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ABSTRACT
Chronic Obstructive Pulmonary Disease (COPD) is 
underestimated, underdiagnosed and often under-
treated in the general population. A survey of 17 struc-
tured questions, delivered to all Belgian pulmonary phy-
sicians (PPs) (116 responses), evaluated diagnosis and 
treatment strategies in accordance with the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) guide-
lines 2010 and assessed opinions about the importance 
of diurnal variation of COPD symptoms. All COPD diag-
noses (37% new cases) were spirometry confirmed. Main 
diagnostic parameters were symptoms (99%), external 
risk factors (99%), clinical examination (97%), exacerba-
tions (96%) and patient mobility (96%). FEV1 (forced 
expiratory volume in 1s) (97%) or FEV1/FVC (ratio of FEV1 
to forced vital capacity) (93%) were used most to assess 
diagnosis and severity. The 3 most important therapeutic 
objectives were symptom relief, preventing exacerba-
tions, and improving quality of life; if these were not 
reached, the preferred strategy (60% of PPs) was adding 
another medication. Treatment strategies varied with 
COPD stage: short-acting β2-agonists (90%) and short-
acting anti-cholinergics (59%) were used for GOLD I dis-
ease, whereas for higher stages long-acting β2-agonists 
(36-48%) and long-acting anti-cholinergics (79%) were
 given with inhaled corticosteroids (21-67%). Symptoms 
were perceived to vary throughout the day, affecting 
quality of life (97%) and mobility (89%). In particular, res-
piratory symptoms were more severe in the morning (51-
92%), leading PPs to adapt treatment (69%). This survey 
demonstrated that management of COPD by PPs in Bel-
gium is generally in line with the GOLD guidelines 2010 
and that they perceive morning symptoms as being fre-
quent and having an impact on patient’s life.
Key words: COPD, pulmonary physicians, symptoms, treatment 
strategy, survey
INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is a leading 
cause of morbidity and mortality worldwide. It is accompanied 
by a negative impact on quality of life resulting in serious eco-
nomic and social burden (1). Yet, its prevalence remains under-
estimated as most patients with stage I (mild COPD) do not 
present with any symptoms or with symptoms that are per-
ceived as normal (2-4). A systematic review performed in 1996 
reported a pooled COPD prevalence of 7.6% for the 28 coun-
tries included in the analysis (1, 5). The international Burden of 
Obstructive Lung Disease (BOLD) study showed that, when 
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and treatment strategies for COPD, in accordance with the 
GOLD guidelines 2010, and their opinion about the impor-
tance of morning symptoms for the initiation of treatment 
and its follow-up.
METHODS 
This survey took place in 2010 and was open to all PPs 
practicing in Belgium (N = 468). Participation to the survey was 
voluntary and no incentive was offered for answering the ques-
tionnaire. Data were collected using a structured questionnaire 
with closed questions available in French or Dutch (available in 
the Online Supplemental material; an English translation is pro-
vided in the Appendix). The questionnaire was designed by a 
group of Belgian experts called the COPD Working Group. It 
was attached to the invitation for a series of AstraZeneca COPD 
Awareness Meetings (“The quest for GOLD – COPD in different 
dimensions”) and delivered by AstraZeneca sales representa-
tives during their regular visits to the PPs during the first two 
quarters of 2010. All questionnaires were provided with a pre-
paid envelope to be sent back to M. Decramer, prinicipal inves-
tigator of the study before the 15th of June, 2010. 
A cover letter from the COPD Working Group accompa-
nied the questionnaire and outlined the objectives of the 
survey: to understand the diagnosis and treatment strategies 
used in COPD patients in usual clinical practice and to explore 
opinions about symptom variation throughout the day in 
COPD patients. In addition, the cover letter specified that all 
information provided would be treated anonymously and 
combined with the information of other PPs to provide an 
overall analysis for Belgium. 
Extra questionnaires were available at the meetings in 
case the participating physicians had not had the opportu-
nity to respond previously: they were able to complete the 
survey before the presentation and the questionnaires were 
directly sent to the prinicipal investigator.
The PPs were asked to answer the questionnaire based on 
either their usual clinical practice, or, for some specific ques-
tions, the treatment of their last 10 new COPD patients. Two 
general questions requested the number of years of profes-
sional experience and the geographic location for the PP. 
The main questionnaire was divided into two parts, each 
based on one of the objectives outlined in the cover letter. 
The first part was related to the patients and was divided into 
five main sections: 
– Origin of the patient 
– Diagnosis and assessment of severity
– Therapeutic goals
– Treatment strategy
– Patient follow-up. 
Each of these sections contained questions that requested 
further information regarding the usual clinical practice of the 
PPs. The use of the GOLD guidelines 2010 by the PPs was 
asked in the sections on diagnosis and assessment of severity 
and treatment strategy. The second part of the questionnaire 
was related to the variability of symptoms and was divided 
into five questions: 
– Do you think that COPD symptoms vary throughout the 
day?
– If yes, at what time of day are they at their most serious?
stages II and higher of COPD are confirmed by spirometry, the 
overall prevalence of these stages is 10%, which is greater than 
typically reported (6). The Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) was set up to increase awareness of 
COPD and the GOLD report (published in 2001, updated in 
2006, 2010 and 2011) provided recommendations for the man-
agement of COPD³. Many different reasons are given by physi-
cians for non-adherence to the GOLD guidelines 2010. For 
instance, lack of familiarity with the guidelines, low self- efficacy, 
and time constraints have been reported as important barriers 
to adherence (7). 
In a COPD survey conducted in Austria where diagnosis 
was confirmed by spirometry, Schirnhofer et al. (8) found that 
GOLD stage I and higher affected 26% of the participants and 
GOLD stage II and higher 11%. By contrast, the prevalence of 
doctor-diagnosed chronic bronchitis, emphysema, or COPD 
in the same population was only 6%. In view of such a high 
discrepancy between general practice screening for COPD 
and diagnosis based on objective lung function measures 
such as spirometry, Schirnhofer et al. (8) concluded that 
awareness of COPD among health professionals was subopti-
mal and needed to be improved. 
Observational studies, conducted in Spain (9) and in the 
USA (10), identified significant variation in the percentage of 
diagnostic spirometries performed in primary care centers, 
with more than a threefold difference between the lowest 
and highest rates of use. 
In Belgium, Vandevoorde et al. (11) revealed “an impor-
tant prevalence of undiagnosed COPD” among current smok-
ers: 17.1% of the patients included had an established COPD 
diagnosis, while the spirometry screening determined a prev-
alence of 46.6% in the same population. Office spirometry 
significantly improves early detection of COPD (12), as screen-
ing for airflow obstruction almost doubles the number of 
known patients with obstructive lung disease. 
The cornerstones of treatment strategies commonly used 
by specialists include pharmacotherapy and rehabilitation in 
addition to smoking cessation. There is accumulating evi-
dence that pharmacotherapy should be started early in the 
course of the disease (13-15). This measure is important as 
decline in both physiological and quality of life aspects occur 
at a considerably faster rate in the early stages of the disease 
(15-16). Combination pharmacotherapies including anticho-
linergics, corticosteroids and β2-agonists are the leading 
treatment strategies (17-18), while non-pharmacological 
strategies take an important part in the management of 
advanced COPD (19).
Diurnal variations in peak expiratory flow have been 
reported for COPD patients (20-21), which are weakly nega-
tively correlated to dyspnoea and fatigue (22). COPD symp-
toms also vary throughout the day, affecting daily activities 
especially in the morning (23). In a telephone survey, later 
expanded through the internet, Partridge et al. (24-25) 
revealed that the majority of COPD patients experienced 
breathlessness, phlegm, cough, wheezing and chest tight-
ness in the morning, while admitting they were not taking 
their medication in time for it to exert its optimal effect.
However, as this is a recent finding, most physicians may not 
be aware of the impact of morning symptoms on patients’ lives.
In the present study, we surveyed Belgian pulmonary 
physicians (PPs) in order to assess their self-declared  diagnosis 
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(51%) or by another PP (16%). One third of patients came on 
their own initiative (33%).
Parameters used to diagnose COPD
All PPs confirmed the COPD diagnosis with spirometry 
and the vast majority made the diagnostic themselves (84%) 
or got it from another specialist [not a PP] (4%), while a 
minority (12%) relied on the diagnostic of a GP. Most patients 
were diagnosed with a GOLD II (41%) or a GOLD III (31%) 
stage; the remaining patients were divided equally between 
GOLD I and GOLD IV stages (14% each).
FEV1 (forced expiratory volume in one second) alone or 
ratio of FEV1 to FVC (forced vital capacity) were used by nearly 
all PPs to assess both diagnosis and severity (Table 2), while 
the percentage of FEV1 reversibility was used less often and 
mainly for diagnosis. Nearly all PPs used a combination of 
lung function, symptoms, external risk factors, clinical exami-
nation, occurrence of exacerbation and patient’s mobility as 
diagnostic criteria (Table 3); other commonly used criteria 
included co-morbidities and quality of life. 
Family history and external risk factors were mainly used 
for diagnosis, while the patient’s mobility, the MRC (Medical 
Research Council) dyspnoea scale, co-morbidities, quality of 
life and frequency of exacerbations were more commonly 
used to assess the severity of COPD.
Among the symptoms used as diagnostic criteria, dysp-
noea, frequent or persistent cough, and sputum production/
expectorations were most often cited (Table 3). Smoking was 
more frequently (41%) stated as a specific risk factor than 
exposure to chemical substances (23%) or air pollution (22%) 
and asthma (14%).
FEV1 (forced expiratory volume in one second), alone or 
as a ratio with FVC (forced vital capacity) was used by nearly 
all PPs to assess both diagnosis and severity (Table 2), while 
the percentage of FEV1 reversibility was used less often and 
mainly for diagnosis.
Therapeutic objectives
We asked the PPs to choose the three most important 
therapeutic objectives from a list of 12 items: symptoms relief, 
improvement of morning symptoms, prevention of respiratory 
function decline, prevention of exacerbations,  prevention of 
hospitalisation, prevention of oral corticosteroids use, preven-
tion of antibiotics use, mortality reduction, prevention or 
reduction of treatment side effects, prevention and treatment 
of COPD complications, improvement of quality of life, 
improvement of patients’ mobility (ability to carry out daily 
tasks), or other. Those selected the most were symptoms relief, 
– Do you think the variability of symptoms throughout the 
day impacts the quality of life of COPD patients?
– Do you think that morning symptoms impact the mobility 
of the patient?
– If you indicated that symptoms are most severe in the 
morning, does this impact your therapeutic approach?
Responses to the questionnaire were collected and analysed 
by G. Gayan-Ramirez at the KULeuven. Missing answers were not 
replaced. The data was summarised as mean ± standard devia-
tion or the percentage of respondents answering the question.
RESULTS
Out of the 468 PPs that were contacted, 116 question-
naires were returned and analyzed (response rate = 25%, 
Table 1). The average practice experience was 15.7 ± 9.9 years 
and the respondents treated on average 72 ± 52 COPD 
patients per month. The responses came from all geographi-
cal areas of Belgium, except Walloon Brabant, with a higher 
proportion from the provinces Antwerp (23%), Liège (16%), 
and Hainaut (14%); the other provinces were evenly repre-
sented except for Luxembourg (2%).
Patient referral
Most patients had been previously diagnosed with COPD 
(63%) and were referred by their general practitioner (GP) 
Table 1: Demographic characteristics of respondents
N 
Contacted 100% 468
Answered 25% 116
Practice experience 15.7 ± 9.9 years 113
Patients per month 72 ± 52 113
Geographical area 116
Antwerp 23%
Liège 16%
Hainaut 14%
Brussels 10%
Flemish Brabant 8%
East-Flanders 7%
West-Flanders 6%
Limburg 5%
Namur 5%
Unknown 4%
Luxemburg 2%
Walloon Brabant 0%
Table 2: Spirometry parameters used to diagnose COPD
Spirometry parameters Used by PPs
(%)
For diagnosis only
(%)
For severity only
(%)
For both
(%)
FEV1 (% of predicted value) 97 2 16 82
FVC (% of predicted value) 58 22a 8a 70a
FEV1 / FVC 93 33a 3a 64a
% of FEV1 reversibility 74 44a 11a 45a
Data analyzed according to the information recorded in the returned questionnaires (N = 116). 
COPD: Chronic Obstructive Pulmonary Disease
FVC: forced vital capacity; FEV1: forced expiratory volume in one second.
a N = 115
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for GOLD II, but 91 and 94% for GOLD III and GOLD IV), or 
mucolytics. Theophylline, oxygen, and physiotherapy were 
mainly prescribed for GOLD III and IV.
Patients follow-up
Most PPs did the patient follow-up themselves (64%), while 
a third of them delegated that responsibility to a GP (35%).
Nearly all PPs declared that they used symptoms to deter-
mine the follow-up treatment of their patients (Table 5); most 
of them also used pulmonary function, external risk factors, 
exacerbations, clinical examination, patient’s mobility or co-
morbidities. Quality of life and family history of COPD were 
reported by a minority of PPs, but objective questionnaires 
were rarely used (10%) to assess the quality of life. Similarly, 
the MRC dyspnoea scale was mentioned by only a few PPs 
(8%). Some of them said they used arterial blood gas analysis 
(8%) or high resolution computed tomography (2%) for their 
follow-up treatment decision.
Dyspnoea, expectorations, and frequent or persistent 
cough were most often cited as specific symptoms to deter-
mine follow-up care, although the frequencies ranged from 
15% to 19% (Table 5). Smoking was more frequently stated as 
a specific risk factor than exposure to chemical substances or 
air pollution and asthma.
Variability of symptoms during the day
The majority of PPs recognised that COPD symptoms vary 
throughout the day. They agreed to various extents that all 
prevention of exacerbations, and improvement of quality of 
life. If the PPs could not reach their objectives, 60% of them 
would add another medication, 14% would increase the doses, 
and 10% would switch medication; but 16% would choose 
another treatment modification. When asked what other type 
of treatment modification, they answered: rehabilitation (61%), 
another inhalation system (11%), integrated care (11%), obser-
vation (8%), and improving compliance (8%).
Treatment strategies
The treatment of newly diagnosed COPD patients was 
usually initiated by a PP (in 62% of cases), or by a GP (34% of 
cases), rarely by a specialist in another domain (5%).
The PPs modulated their treatment strategies according 
to the COPD stage (Table 4). For patients with GOLD I disease, 
they mainly prescribed short acting β2-agonists (SABA) and 
short acting anti-cholinergics (SAAC), both administered by 
inhalation via pMDIs or DPIs. The strategies changed for the 
higher GOLD stages (II to IV): fewer SABA and SAAC were pre-
scribed, and when prescribed for advanced COPD, nebulisa-
tion was used instead of pMDI or DPI. Also, more long acting 
anti-cholinergics (LAAC) and long acting β2-agonists (LABA) 
were used in combination with inhaled corticosteroids in 
advanced COPD. In contrast to the GOLD guidelines 2010, 
oral corticosteroids were prescribed surprisingly often (15 
and 34% for GOLD III and GOLD IV). For those patients with 
higher GOLD stages, the usual prescription was a fixed com-
bination of inhaled corticosteroids and LABA (ICS/LABA, 24% 
Table 3: Parameters used in the diagnosis of COPD
Diagnosis parameters Used by PPs 
(%)
For diagnosis only
(%)
For severity only
(%)
For both
(%)
Pulmonary function 100 1 3 96
Exposure to external risk factors 99 54 7 39
Smoking 41
Chemical substances 23
Pollution 22
Asthma 14
Symptoms 99 14a 8a 78a
Dyspnoea 19
Frequent/persistent cough 16
Sputum expectorations 16
Wheezing 12
Tightness 12
Morning symptoms 11
Nocturnal awakening 7
Fatigue 6
Others 1
Physical examination 97 15 17 69
Occurrences of exacerbation 96 4 43 53
Patient’s mobility 96 3 61 36
Co-morbidities 82 8 54 38
Quality of life 72 5 50 45
Family history of COPD 46 65 10 25
MRC dyspnoea scale 33 16b 55b 29b
Other 20 15 60 25
Data analysed according to the information recorded in the returned questionnaires (N = 116). 
MRC: Medical Research Council.
COPD: Chronic Obstructive Pulmonary Disease
a N = 114
b N = 115
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respiratory symptoms had the highest intensity in the morn-
ing (Figure 1). In particular, most PPs noted cough with 
expectoration (92%), dyspnoea (89%), and frequent or persis-
tent cough (75%), while wheezing and tightness were 
reported by half of them (59% and 51%, respectively). Gen-
eral symptoms were observed more often at other times of 
the day: loss of appetite at noon (33%), fatigue mostly in the 
afternoon (41%), and depression/anxiety (48%) in the even-
ing.
When asked if the variability of symptoms during the day 
impacted the quality of life and the mobility of the patients, 
97% of the PPs declared that it affected the quality of life, and 
89% of the PPs said it affected the mobility of patients. Most 
PPs believed that impairments in mobility occurred mainly in 
the morning (84%), and much less at other times of the day 
(16% stated at noon, 9% the afternoon, 6% in the evening, 
and 5% at night).
Finally, 69% of the PPs declared that they would change 
their therapeutic strategy for the COPD patients with more 
severe morning symptoms. In particular, they suggested to 
take the medication earlier (49%), to increase the dose of 
bronchodilatators (21%) and to a lesser extent that of inhaled 
corticosteroids (7%). Other treatment modifications are listed 
in Table 6.
DISCUSSION
To our knowledge, data on the awareness and treatment 
strategies of COPD are not available for Belgium and the pre-
sent survey fills the gap. 116 experienced PPs representing 
nearly all geographical areas of Belgium reported that they 
assessed COPD diagnosis and severity based on a combination 
Table 4: COPD treatment strategies according to the GOLDa stage of the patient
Strategies GOLD I (%) GOLD II (%) GOLD III (%) GOLD IV (%)
Short acting β2-agonists Inhalation via DPI 90 66 62 59
Nebulisation 0 1 4 17
Long acting β2-agonists 4 48 40 36
Short acting anti-cholinergics Inhalation 59 48 45 41
Nebulisation 0 0 3 15
Long acting anti-cholinergics 7 79 79 79
Oral corticosteroids 1 5 15 34
Inhaled corticosteroids Low daily doseb 3 12 9 4
Moderate daily dose 0 9 45 27
High daily dose 0 0 13 30
Fixed combination (ICS/LABAc) 0 24 94 91
Leukotriene antagonists 0 0 1 2
Theophylline 1 5 16 51
Mucolytics 9 24 44 53
Oxygen 2 3 22 89
Physiotherapy 3 17 59 76
Others 2 3 8 10
Data analysed according to information recorded in the returned questionnaires (N = 116). The respondents could choose more than one item, therefore 
the totals do not add to 100%.
COPD: Chronic Obstructive Pulmonary Disease
a GOLD: Global Initiative for Chronic Obstructive Lung Disease.
b Low dose: ≤ 500 µg BDP/day; moderate dose: > 500-1000 µg BDP/day; high dose: > 1000 µg BDP/day 
c ICS/LABA: inhaled corticosteroid/long-acting β2-agonists.
Table 5: Criteria used for determining follow-up care for 
COPD patients
Parameters Used by PPs(%)
Symptoms 99
Dyspnoea 19
Expectorations 16
Frequent/persistent cough 15
Tightness 12
Morning symptoms 12
Wheezing 11
Nocturnal awakening 8
Fatigue 6
Others 1
Pulmonary function 91
Exposure to external risk factors 91
Smoking 46
Chemical substances 22
Pollution 22
Asthma 10
Exacerbation 86
Clinical examination 79
Patient’s mobility 68
Co-morbidities 56
Quality of life 40
Other 19
Family history of COPD 13
MRC dyspnoea scale 8
Data analysed according to information recorded in the returned 
questionnaires (N = 116). 
COPD: Chronic Obstructive Pulmonary Disease
MRC: Medical Research Council.
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Our study confirms the impact of morning symptoms on 
the quality of life in COPD patients, which was already 
described by Kessler et al  (23) and Partridge et al  (24-25). We 
also showed that respiratory symptoms are more frequent in 
the morning, while other symptoms are more prevalent in the 
afternoon and the evening (Figure 1). The most cited strategy 
to treat severe morning symptoms was to advise to take med-
ication earlier. This could have implications towards the gen-
eral management of COPD patients: intake of bronchodilata-
tors could be advised before leaving bed, especially 
bronchodilatators with fast onset.
The present survey was conducted in line with new devel-
opments in the knowledge, detection and treatment of COPD 
for a better understanding of early stages of the disease (16). 
Our study extends the survey conducted by Vandevoorde et 
al. (11) which was restricted to the detection of COPD in a 
population of at-risk patients (current smokers with a smok-
ing history of at least 15 pack-years). In this survey, 37% of the 
COPD patients were diagnosed during their first visit to a PP. 
This underscores the need for improved COPD detection in 
primary care. In particular, GPs should systematically refer 
smokers or ex-smokers with suggestive complaints to a PP to 
perform a spirometry test to objectively detect COPD, or per-
form the spirometry test themselves (after appropriate train-
ing). Patients often do not seek medical help until they have 
more advanced symptoms. Furthermore, the poor correlation 
between symptoms and the degree of lung function impair-
ment in the early stages of COPD is well documented. This 
situation will probably evolve towards a better usage of diag-
nostic parameters, as the revision of the GOLD guideline rec-
ommends a quantitative method to assess symptoms severity 
(mMRC dyspnoea score or COPD Assessment Test [CAT] score) 
(3). Our data were collected before the 2011 GOLD update 
was issued, hence under reporting the use of symptoms 
scores (MRC dyspnea score, CAT score) as marker of COPD 
severity.
The international BOLD study reported a higher than 
expected prevalence (10% of the general population) of stage 
II or higher COPD (6). Based on the last 10 new COPD patients 
of these PPs, our data also revealed a high prevalence of 
GOLD stages II to IV (86%) among Belgian COPD patients. 
It should be stressed that this repartition over the GOLD 
severity stages pertains to pulmonary physicians and not to 
general practitioners. It is expected that the latter would 
reflect better the severity seen in the general population. 
We have shown that, although these PPs used spirom-
etry, symptoms, and exposure to risk factors to confirm 
COPD, the key indicators recommended by the GOLD guide-
lines 2010 were not used routinely, namely dyspnoea (19%), 
chronic cough (18%), and chronic sputum production (16%). 
However, the questionnaire used in this survey did not fur-
ther investigate the reasons for these low frequencies. It was 
also surprising that only 41% of the PPs used smoking his-
tory as a diagnostic criterion, knowing that 90% of the COPD 
patients in our countries are smokers or ex-smokers. This 
unexpected low usage could result from the design of the 
questionnaire.
In general, the self-declared management of COPD by 
Belgian PPs is reasonably well in line with the GOLD guide-
lines 2010. Nevertheless, at least three elements in the pre-
sent survey deviate from these guidelines. 
of parameters and confirmed diagnosis with spirometry. Their 
main treatment objectives were symptom relief, prevention of 
exacerbations, and improvement of quality of life. When those 
objectives could not be reached, most of them would add 
another medication to the treatment regimen before increas-
ing the dose or make other treatment modifications. As 
expected, treatment strategies were modulated according to 
the COPD stage, with short-acting drugs and nebulised admin-
istration prescribed for incipient COPD, while long-acting drugs 
and formulations inhaled via pMDIs or DPIs were prescribed 
mainly for advanced stages, together with ICS and fixed com-
bination ICS/LABA. The PPs observed that a variability of symp-
toms during the day, particularly in the morning, affected the 
quality of life and mobility of their patients. A worsening of 
respiratory symptoms in the morning influenced their thera-
peutic strategy towards recommending medication be taken 
earlier in the day, increasing the dose, adding another medica-
tion or pulmonary rehabilitation.
Figure 1: Intensity of COPD symptoms as evaluated by PPs  
The intensity of symptoms during the day was assessed by the 
pulmonologists during patients’ follow-up visits. Results were 
pooled as respiratory symptoms (cough with expectoration, 
dyspnoea, frequent or persistent cough, wheezing, and tight-
ness) or other symptoms (depression/anxiety, loss of appetite, 
fatigue, and other) and expressed as average percentage in 
function of the time of the day (morning: 6-10 h; noon: 10-14 
h; afternoon: 14-18 h; evening: 18-22 h; night: 22-6 h). Several 
time periods could be checked for each symptom.
Table 6: Impact on therapeutic strategy of severe 
morning symptoms
Modified therapeutic strategies %
Take medication earlier 49
Increase dose 28
Start faster acting treatments 25
Pulmonary rehabilitation 23
Add another medication 20
Replace one of the medications 5
Other 2
Data analysed according to information recorded on pulmonologists’ 
questionnaires (N = 116). 
Several therapeutic strategies could be checked. 
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It was striking that PPs were well aware of the importance 
of morning symptoms, particularly dyspnoea, cough with 
expectoration, and frequent or persistent cough. These symp-
toms were also recognised to affect quality of life and mobil-
ity. The observation is striking, as the literature on these 
symptoms in COPD is relatively scarce and recent (23-25). This 
suggests that the occurrence of morning symptoms and their 
consequences for quality of life and mobility is likely to be a 
common clinical observation and further confirms the impor-
tance of these symptoms.
In conclusion, this survey showed that Belgian PPs had an 
acceptable self-declared adherence to the GOLD guidelines 
2010, although some clear discrepancies were present as 
well. These discrepancies pertained to the use of symptoms 
and pulmonary function variables in the diagnosis of COPD 
and the overuse of chronic treatment with oral corticoster-
oids. In contrast to our expectations, Belgian PPs were well 
aware of morning symptoms and their impact on patients’ 
lives.
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First, 84% of Belgian PPs use the percentage of FEV1 pre-
dicted in the diagnosis of COPD (2% for diagnosis only and 
82% for diagnosis and assessment of severity), whereas 
strictly according to the guidelines it should only be used for 
the assessment of severity. Conversely, the FEV1/FVC ratio was 
used for the assessment of severity by 3% of PPs and by 64% 
of PPs for diagnosis and assessment of severity, while it 
should only be used for diagnosis. This is because in the latter 
stages of the disease, disease progression will reduce both 
FEV1 and FVC. Hence, severity will increase while the FEV1/
FVC ratio remains unchanged. It should also be noted that a 
recent Belgian study showed that in current practice, patients 
referred to a PP by their GP for differential diagnosis are usu-
ally submitted to a heterogeneous series of tests (26).
Second, the use of a bronchodilator test is needed in 
spirometry to assess the reversibility of the airflow obstruc-
tion. Our survey did not differentiate between spirometry 
performed with or without a bronchodilator, which can 
potentially lead to an overestimation of COPD prevalence 
(27). Only 74% of PPs used the percent reversibility of FEV1 as 
a relevant parameter, and 11% of the PPs considered this 
parameter a measure for the severity of COPD rather than a 
diagnostic argument.
Third, oral steroids are still commonly prescribed in GOLD 
stage III and IV patients, while strictly there are no indications 
for chronic treatment with these drugs in COPD. Indeed the 
side-effects of oral steroids often outweigh the benefits (28). 
However, the excess use of oral steroids in these patients 
might be the sign of an overall worsening in the COPD popu-
lation over the years and needs further study.
It should be noted that the use of LABA reported by the 
PPs in this survey was collected before indacaterol (a once-
daily LABA) was available on the Belgian market.
The results of this survey should be read in the light of 
several methodological limitations. We did not ask if another 
spirometry test was performed 6 to 8 weeks later. This would 
confirm that the patient had indeed COPD and avoid possible 
confusion with asthma (27). 
The recruitment of PPs via medical representatives could 
also have introduced a bias as we cannot confirm that all Bel-
gian PPs were visited on time for the survey; factors such as 
unavailability, absence, or visit denial make it unlikely that all 
PPs received the questionnaire on time. Nevertheless, 
responders were distributed in all geographical areas of Bel-
gium, Walloon Brabant being probably assimilated with Brus-
sels’ area.
The response rate of 25% also limits the generalisation of 
our results, although it is not surprising given that participa-
tion to the survey was not compulsory and no incentive of 
any kind was ever linked to the invitation to the AstraZeneca 
meetings. The response rate in our study is similar to that 
obtained in a previous survey (29) performed among all Bel-
gian PPs in December 2001 – January 2002, with a response 
rate of 24%. At that time, the repartition of responders was 
distributed between 59% in Dutch speaking areas and 41% 
in French speaking areas, which is comparable to our study, 
with 49% in Dutch and 37% in French speaking areas, respec-
tively (to the exclusion of 10% of responders in Brussels and 
4% unspecified). We can therefore assume that in spite of a 
modest response rate, our results are representative of the 
Belgian PPs habitual practice.
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Appendix:
COPD Awareness Program SP questionnaire
Treatment schedule COPD
Dear Doctor,
Thank you for filling in this questionnaire. 
This survey will allow us to understand the treatment schedules you are using for your COPD patients in your daily 
practice. We will also try to determine whether the symptoms your COPD patients experience, are variable over the course of 
the day.
May we ask you to fill in this questionnaire as precisely as possible?
We would also like to clarify that all collected data in the framework of this study will be handled in a completely anonymous 
manner. Your data will be merged with data from your colleagues in order to attain a global analysis at the Belgian level.
Sincerely yours,
Prof. Dr. M. Decramer 
President, COPD Working Group 
Years of Practice Experience:
 Years
Province:
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1. Patients
1.1  How many COPD (chronic obstructive pulmonary disease) patients do you see on average in a representative 
month in your practice?
  Patients per month
Patient’s referral source
1.2  When you think of the last 10 new COPD patients who came for a consultation, how many were:
  patients who had not yet been diagnosed and/or treated …… /10
  COPD patients who had already been diagnosed and/or treated …… /10
 TOTAL = 10 patients
1.3 Can you specify where these last 10 new COPD patients were referred from?
  Patient was referred by the general practitioner …… /10
  Patient came on own initiative …… /10
  Patient was referred by a colleague of a different specialty …… /10
  Which specialty? ……………
TOTAL = 10 patients
Diagnosis and severity evaluation 
1.4  In how many of these last 10 new COPD patients was the diagnosis, based on spirometry, determined by:
  yourself  …… /10
  the general practitioner …… /10
  a colleague of a different specialty …… /10
  Which specialty? ……………
TOTAL = 10 patients
1.5 How would you classify these last 10 new COPD patients?
  GOLD stage I …… /10
  GOLD stage II …… /10
  GOLD stage III …… /10
  GOLD stage IV …… /10
TOTAL = 10 patients
1.6  Which parameters do you take into account when determining the diagnosis and/or the COPD severity stage?
 Please specify whether this applies to the diagnosis and/or severity of the disease.
  Symptomatology ( Diagnosis /  Severity /  Both)
  o Wheezing o Tightness o Frequent/chronic coughing
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  o Expectorations o Waking up at night o Dyspnoea
  o Morning symptoms o Fatigue o Other: ………………
  Family history of COPD ( Diagnosis /  Severity /  Both)
  Exposure to risk factors ( Diagnosis /  Severity /  Both)
  o Smoking o Pollution o Chemical substances o Asthma
  Patient’s quality of life ( Diagnosis /  Severity /  Both)
  o Measured by means of an objectively validated questionnaire ( Diagnosis /  Severity /  Both)
  Patient’s mobility (ability to perform daily tasks)
  ( Diagnosis /  Severity /  Both)
  Occurrence of exacerbations ( Diagnosis /  Severity /  Both)
  Co-morbidities ( Diagnosis /  Severity /  Both)
  Questionnaires (e.g. MRC questionnaire) ( Diagnosis /  Severity /  Both)
  Patient’s physical examination ( Diagnosis /  Severity /  Both)
  Pulmonary function ( Diagnosis /  Severity /  Both)
  Other: ………………… ( Diagnosis /  Severity /  Both)
1.7 When you perform spirometry, which parameter do you use to determine the diagnosis and COPD severity?
  FEV1 (% of the predicted value) ( Diagnosis /  Severity /  Both)
  FVC (% of the predicted value) ( Diagnosis /  Severity /  Both)
  FEV1/FVC ( Diagnosis /  Severity /  Both)
  % reversibility of FEV1 ( Diagnosis /  Severity /  Both)
Therapeutic goals
1.8  When you initiate treatment for a COPD patient, which are the 3 most important goals to you (in order of 
importance, with 1 = most important)?
   …… Symptom relief
   …… Improvement of morning symptoms
   …… Prevention of worsening of pulmonary function 
   …… Prevention of exacerbations
   …… Prevention of hospitalisations 
   …… Prevention of oral corticosteroids use 
   …… Prevention of antibiotics use 
   …… Decrease in mortality
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   …… Prevention or minimisation of adverse effects of the treatment
   …… Prevention and treatment of COPD complications 
   …… Improvement of patients’ quality of life 
   …… Improvement of patients’ mobility (ability to perform daily tasks)
   …… Other, please specify 
1.9 What do you do if the initiated treatment does not reach therapeutic goals?
  Increase the dose of one of the medicines 
  Add a medicine to the current therapy 
  Switch the medicine
  Other type of treatment change: ……………………………………………
Treatment strategy
1.10 When you think of your last 10 new COPD patients, in how many patients was treatment initiated by:
  yourself …… /10
  the general practitioner …… /10
  a colleague of another specialty …… /10
  Which specialty?
TOTAL = 10 patients
1.11  We will now ask you to specify the treatment you usually prescribe for COPD 
  GOLD stage I, II, III and IV patients. Please specify the initial treatment for each group by using the table below. 
(Indicate with an ‘x’)
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Gold stage I Gold stage II Gold stage III Gold stage IV
Short-acting β2-mimetics  via inhalation
 via nebulisation
 via inhalation
 via nebulisation
 via inhalation
 via nebulisation
 via inhalation
 via nebulisation
Long-acting β2-mimetics 
Short-acting Anticholinergics  via inhalation
 via nebulisation
 via inhalation
 via nebulisation
 via inhalation
 via nebulisation
 via inhalation
 via nebulisation
Long-acting Anticholinergics 
Oral corticosteroids 
Inhalation 
corticosteroids
low daily dose:
< 500 µg BDP/day
 low daily dose  low daily dose  low daily dose  low daily dose
moderate daily dose:
> 500 µg BDP/day
  moderate daily 
dose
  moderate daily 
dose
  moderate daily 
dose
  moderate daily 
dose
high daily dose:
< 500 µg BDP/day
 high daily dose  high daily dose  high daily dose  high daily dose
Fixid combinations 
(ICS/LABA)
Leukotriene  
receptor-antagonists
Theophylline 
Mucolytics 
Oxygen 
Physical therapy 
Other (specify) 
Patient follow-up
1.12 When you think of your last 10 new COPD patients, how many patients had treatment follow-up done by:
  yourself …… /10
  the general practitioner …… /10
  a colleague of another specialty …… /10
  Which specialty?
TOTAL = 10 patients
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1.13  Which parameters do you take into consideration when you do COPD patient follow-up?
  Symptomatology
  o Wheezing o Tightness o Frequent/chronic coughing
  o Expectorations o Waking up at night o Dyspnoea
  o Morning symptoms o Fatigue o Other: ………………
  Family history of COPD 
  Exposure to risk factors
  o Smoking o Pollution o Chemical substances o Asthma
  Patient’s quality of life
  o Measured by means of an objectively validated questionnaire
  Patient’s mobility (ability to perform daily tasks)
  Occurrence of exacerbations
  Co-morbidities
  Questionnaires (e.g. MRC questionnaire) 
  Patient’s physical examination
  Pulmonary function
  Other: ………………… 
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1. Symptom variability
2.1 Do you think that symptoms related to COPD can be variable over the course of the day?
  Yes
  No
2.2  If yes, can you indicate with an ‘x’ for each symptom when you think they are most severe (at what time of 
the day)?
 You can indicate multiple time periods
Morning 
(between 6am 
and 10 am)
Noon 
(between 10am 
and 2 pm)
Afternoon 
(beween 2pm 
and 6pm)
Evening 
(between 6pm 
and 10pm)
Night 
(between 10pm 
and 6am)
Dyspnea 
Wheezing 
Frequent or  
continuous coughing
Cough with  
expectorations
Fatigue 
Tightness 
Lack of appetite 
Depression/Fear 
Other: 
2.3  Do you think that the variability of these symptoms over the course of the day has an impact on your COPD 
patients’ quality of life?
  Yes
  No
2.4  Do you think that the variability of these symptoms over the course of the day has an impact on your COPD 
patients’ mobility?
 Mobility is hereby defined as the ability to perform daily tasks.
  Yes
  No
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2.5  If yes, please indicate with an ‘x’ when, according to you, the variability of symptoms has the most impact on 
your COPD patients’ mobility?
Morning  
(between 6am  
and 10 am)
Noon 
(between 10am 
and 2 pm)
Afternoon  
(beween 2pm  
and 6pm)
Evening  
(between 6pm  
and 10pm)
Night 
(between 10pm 
and 6am)
 
 
2.6  If you indicated that the symptoms your patients experience are the most severe over the course of 
the morning (between 6am and 10am), does this have an impact on your therapeutic approach?
  Yes
  No
2.7 If yes, which?
  You increase the dose:
  o inhalation corticosteroids   o bronchodilators
  You recommend that the patient take his/her medication earlier in the morning 
  You add a medicine to the current treatment 
  You start treatment with a quicker effect
  You replace one of the medicines 
  You initiate treatment with pulmonary revalidation 
  Other: …………………………………………………………………………………
Thank you for your collaboration!
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